Liraglutide in Treatment of Diabetes Mellitus Type 2: Systematic Review and Bibliometric Analysis Over The Last Two Decades

Abstract

Background: Type 2 diabetes mellitus (T2DM) is a chronic progressive metabolic disorder and liraglutide is one of the glucagon-like peptide-1 (GLP-1) agonists that are used to decrease glucose levels in the blood and help in weight loss in patients with T2DM. Bibliometric analysis is one of the most common statistical methods used to evaluate the credibility, quality, and impact of scholarly work. Methods: We performed a systematic review and bibliometric analysis over the last two decades (2000-2020) by search on the WOS database for studies published in the literature on June 2021 by using relevant keywords ("Diabetes Mellitus, Type II") AND (Liraglutide). We extract the data of the most ten cited articles, journals, countries, and years. The bibliometric analysis was performed by HistCite software. Results: There are 2500 records entered the bibliometric analysis and divided into 1813 articles and 687 reviews. The highest-cited paper was "Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes". The LANCET was the top-cited journal with a 7599 total global citation score (TGCS). Novo Nordisk AS and USA were the most cited institution, countries in order, and with a top number of publication records. Among the most cited articles, 2016 was the first global citation year score (n=9585), while 2020 was the top in a number of publications records (n=310). Conclusion: Our bibliometric analysis provides both quantitative and qualitative analyses and gives insight on the citation frequency of top-cited articles published in using liraglutide in the treatment of patients with diabetes mellitus type 2.